Brian V. Jegasothy

Brian V. Jegasothy
Born (1943-03-03)March 3, 1943
Died April 20, 2001(2001-04-20) (aged 58)
Nationality Sri Lanka
Occupation Physician
Years active 31
Known for Dermatology
Medical career
Research Immunologic Mechanisms

Brian V. Jegasothy (born March 3, 1943 in Colombo, Sri Lanka) was a dermatologist and visiting professor at over 50 Universities.[1] and clinics, and was the Chairman of the Department of Dermatology at the University of Pittsburgh from 1987 to 1999.[2][3]

Jegasothy helped develop an improved treatment for a rare kind of cancer known as cutaneous T-cell lymphoma.[4] Jegasothy and his colleagues at Yale University established the standard photopheresis technique used to treat serious cases of cutaneous T-cell lymphoma[5] He also aided in the study of immunobullous diseases, which is when the immune system attacks the skin and causes it to blister and fall off.[6]

He helped in the development of a topical form of FK506, which is an anti-rejection drug invented by organ transplant researchers at Pittsburgh. Topical FK506 has been used to treat conditions such as psoriasis in addition to the rashes that transplant patients develop.[7]

Jegasothy was also the founder of the Asian Indian Christian Church of Pittsburgh, which unites members of Pittsburgh's Indian, Sri Lankan, Pakistani and Bangladeshi communities.[8]

Early life and career

Brian V. Jegasothy was a boarder and scholar at Wesley College, Colombo. He won the Hill Medal in 1960 and obtained a direct entry to the new Medical Facility in Peradeniya. While he worked at a local bank for a short time, he met his future wife Dr. Juliet Jegasothy, medical director for hospital accreditation at the University of Pittsburgh Medical Center.[2]

In 1961, he earned his bachelor's degree for Biology and in 1966, he earned his medical degree, both at the University of Ceylon. He also received a master's degree from University of Pennsylvania.[9]

Brian V. Jegasothy later came to the United States to further his studies. His mentor at a New York city hospital then recommended him for a dermatology residency at Yale.[2] From Yale, Jegasothy's career took him to Duke University, where he worked as a clinician, educator, administrator and researcher,[10] receiving numerous grants from pharmaceutical companies, foundations, and the National Institutes of Health.[11] He later joined the University of Pennsylvania, before he became chairman of the dermatology department at the University of Pittsburgh in 1987, a post he held until 1999.[12]

Throughout his career Brian V. Jegasothy was a visiting professor at countless national and international universities, including Yale University, Cambridge University, and New York University.[13] He worked on identifying a series of T-cell cytokines, documenting immunologic deficiencies in several dermatologic illnesses, evaluating extracorporeal photopheresis and pioneering the studies of oral FK506. He also served on numerous editorial boards[14][15] and was a prominent participant and leader in multiple dermatological organizations.

Professional Associations

Brian V. Jegasothy had served in many leadership positions,[16] including:

  • Board of Directors for the Society of Investigative Dermatology, 1992-2001.
  • Board of Directors for the Association of the Professors of Dermatology, 1989-2001.
  • Chairman of the Scientific Program Committee for the Society of Investigative Dermatology, 1985-1990.
  • Chairman of the Scientific Awards Committee for the American Academy of Dermatology, 1985-1988.
  • President of the American Society for Dermatologic Allergy and Immunology, 1984.
  • Examiner for the American Board of Dermatology.

Lectures

Brian V Jegasothy lectured dermatologists and physicians at national conferences and clinics, including the Mayo Clinic, Mount Sinai Medical Center, the American Academy of Dermatology Annual Meeting and the American Dermatologic Association Annual Meeting. Jegasothy also lectured at prominent international conferences and universities including Cambridge University, the Indian Dermatologic Association Annual Meeting, the World Congress of Dermatology, the University of Kiel, and the Japanese Society for Investigative Dermatology.

Publications

Brian V. Jegasothy was the author of several books[17] and hundreds of scientific articles, abstracts and chapters.[18][19][20][21] He has published in the JAMA Dermatology,[22] the Journal of the American Academy of Dermatology,[22][23] the Journal of Investigative Dermatology,[24][25][26] and the New England Journal of Medicine[5]

References

  1. ↑ https://books.google.com/books?id=Gvc2AQAAMAAJ&pg=PT101%5Bfull+citation+needed%5D
  2. 1 2 3 Lazarus, Gerald S. (2002). "Brian Jegasothy, 1943-2001". Journal of the American Academy of Dermatology. 47 (6): 973–4. doi:10.1067/mjd.2002.120926.
  3. ↑ "Archived copy". Archived from the original on 2016-03-04. Retrieved 2014-12-23.
  4. ↑ http://www.clfoundation.org/sites/default/files/events/CLF_PEF_agenda_Pittsburgh_12.pdf%5Bfull+citation+needed%5D
  5. 1 2 Edelson, Richard; Berger, Carole; Gasparro, Francis; Jegasothy, Brian; Heald, Peter; Wintroub, Bruce; Vonderheid, Eric; Knobler, Robert; Wolff, Klaus; Plewig, Gerhard; McKiernan, Glynis; Christiansen, Inger; Oster, Martin; Honigsmann, Hubert; Wilford, Hubert; Kokoschka, Eva; Rehle, Thomas; Perez, Maritza; Stingl, George; Laroche, Liliane (1987). "Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal Photochemotherapy". New England Journal of Medicine. 316 (6): 297–303. doi:10.1056/NEJM198702053160603. PMID 3543674.
  6. ↑ https://news.google.com/newspapers?nid=1129&dat=20010426&id=Q4ZIAAAAIBAJ&sjid=cXADAAAAIBAJ&pg=6643,4360645%5Bfull+citation+needed%5D
  7. ↑ http://www.apnewsarchive.com/1991/Researchers-Anti-Rejection-Drug-Promising-for-Immune-Disease/id-06cf1564214a1beb915ba44ae6f11f2a%5Bfull+citation+needed%5D
  8. ↑ https://www.facebook.com/media/set/?set=a.674305002604875.1073741842.139723362729711&type=3%5Bfull+citation+needed%5D%5Bself-published+source?%5D
  9. ↑ http://www.utimes.pitt.edu/?p=1776%5Bfull+citation+needed%5D
  10. ↑ http://dermatology.duke.edu/files/pictures/Hall%20Essay%20on%20Duke%20Dept%20of%20Dermatology.pdf%5Bfull+citation+needed%5D
  11. ↑ http://hyluniahymedpro.com/beginning-and-discovery.html%5Bfull+citation+needed%5D
  12. ↑ http://www.hylunia.com/ingredient-dictionary/hyaluronic-acid-hyaluronic-complex-solution-2%5Bfull+citation+needed%5D
  13. ↑ "Archived copy" (PDF). Archived from the original (PDF) on 2016-03-04. Retrieved 2014-12-23.
  14. ↑ http://archderm.jamanetwork.com/article.aspx?articleid=477691&resultClick=3%5Bfull+citation+needed%5D
  15. ↑ http://www.nature.com/jid/journal/v114/n4/full/5600678a.html%5Bdead+link%5D%5Bfull+citation+needed%5D
  16. ↑ "Archived copy" (PDF). Archived from the original (PDF) on 2016-03-19. Retrieved 2015-04-09.
  17. ↑ http://www.abebooks.com/Dermatology-Diagnosis-Therapy-Edward-Bondi-Brian/13217747888/bd
  18. ↑ Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J (2001). "Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma". Journal of Clinical Oncology. 19 (2): 376–88. doi:10.1200/jco.2001.19.2.376. PMID 11208829.
  19. ↑ Rook, Alain H.; Jegasothy, Brian V.; Heald, Peter; Nahass, George T.; Ditre, Chérie; Witmer, William K.; Lazarus, Gerald S.; Edelson, Richard L. (1990). "Extracorporeal Photochemotherapy for Drug-Resistant Pemphigus Vulgaris". Annals of Internal Medicine. 112 (4): 303–5. doi:10.7326/0003-4819-112-4-303. PMID 2297209.
  20. ↑ Jegasothy, Brian; Jacobson, Coleman; Levine, Norman; Millikan, Larry; Olsen, Elise; Pinnell, Sheldon; Cole, Gary; Weinstein, Gerald; Porter, Marvin (1985). "Clobetasol Propionate Versus Fluocinonide Creams in Psoriasis and Eczema". International Journal of Dermatology. 24 (7): 461–5. doi:10.1111/j.1365-4362.1985.tb05821.x. PMID 3902682.
  21. ↑ Gallo RC, Kalyanaraman VS, Sarngadharan MG, Sliski A, Vonderheid EC, Maeda M, Nakao Y, Yamada K, Ito Y, Gutensohn N, Murphy S, Bunn PA, Catovsky D, Greaves MF, Blayney DW, Blattner W, Jarrett WF, zur Hausen H, Seligmann M, Brouet JC, Haynes BF, Jegasothy BV, Jaffe E, Cossman J, Broder S, Fisher RI, Golde DW, Robert-Guroff M (1983). "Association of the human type C retrovirus with a subset of adult T-cell cancers". Cancer Research. 43 (8): 3892–9. PMID 6602653.
  22. 1 2 Carroll PB, Rilo HL, Abu Elmagd K, Johnson N, Carter C, Wright H, Jegasothy B, Starzl TE, Van Thiel DH (1994). "Effect of tacrolimus (FK506) in dystrophic epidermolysis bullosa: rationale and preliminary results". Archives of Dermatology. 130 (11): 1457–8. doi:10.1001/archderm.130.11.1457. PMID 7526802.
  23. ↑ Edelson, Richard; Vonderheid, Eric; Jegasothy, Brian (1986). "Cutaneous lymphoma". Journal of the American Academy of Dermatology. 14 (6): 1073–7. doi:10.1016/S0190-9622(86)80179-7.
  24. ↑ Hunt SJ, Charley MR, Jegasothy BV (1992). "Cutaneous T-cell lymphoma: utility of antibodies to the variable regions of the human T-cell antigen receptor". Journal of the American Academy of Dermatology. 26 (4): 552–8. doi:10.1016/0190-9622(92)70079-u. PMID 1534567.
  25. ↑ Jegasothy, Brian V.; Humeniuk, John M. (1981). "Darier's Disease: A Partially Immunodeficient State". Journal of Investigative Dermatology. 76 (2): 129–32. doi:10.1111/1523-1747.ep12525466. PMID 7007519.
  26. ↑ "Establishment of a Human Cutaneous T-Cell Lymphoma in C.B-17 SCID Mice". Journal of Investigative Dermatology. 94: 381–384. doi:10.1111/1523-1747.ep12874500. Archived from the original on 2016-01-20. Retrieved 2014-12-23.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.